Cohen Cheryl 4

What Happened Cheryl Cohen, a director of Celldex Therapeutics (CLDX), received a derivative award on June 25, 2026: 26,000 shares reported as a grant (derivative/security acquisition) at $0.00 per share. The filing identifies this as an option grant under Celldex’s 2021 Omnibus Equity Incentive Plan. This was an award of options (a compensation grant), not an open-market purchase or sale, so it does not represent an immediate cash transaction.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within the required reporting window).
• Reported as 26,000 derivative shares granted at $0.00 (reflects an option grant rather than a cash purchase).
• Shares owned after the transaction: not disclosed in the filing.
• Footnote: grant made pursuant to the Issuer’s 2021 Omnibus Equity Incentive Plan.
• No 10b5-1 plan, tax withholding, or cashless exercise noted in this filing.

Context An option grant gives the holder the right to acquire common shares in the future (often subject to vesting and an exercise price); it is compensation rather than an immediate market bet by the insider. Such grants are common for directors and executives and should be viewed as part of pay/retention practices rather than a direct signal of trading intent.